


AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listing of claims in the application. For the Examiner's convenience, a complete listing of all claims, incorporating the amendments made herein, is attached as Appendix A.

Listing of Claims:


Claims 1-97 are canceled.

Claim 98. (Currently amended) ~~The compound of claim 97, wherein R₁' is 4-chlorobenzyl, R₂ is isopropyl, and R₅ is 2-aminoethyl;~~ A compound of the formula:



03
namely {2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine.


Claim 99. (Currently amended) ~~The compound of claim 97, wherein R₁' is 4-chlorobenzyl, R₂ is isopropyl, and R₅ is 2-aminopropyl;~~ A compound of the formula:



namely {2-[(2-aminopropyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine.

Claims 100-105 are canceled.

Claim 106. (Currently amended) ~~The compound of claim 124, wherein R₁' is 4-chlorobenzyl and R₂ is isopropyl,~~ A compound of the formula:



namely 2-([9-(methylethyl)-6-(3-quinolylamino)purin-2-yl]amino)ethan-1-ol.

03
Claims 107-108 are canceled.

Claim 109. (Currently amended) A method of inhibiting a cell cycle kinase characterized as CDK2, comprising administering to a mammal in need thereof a therapeutically effective dose of ~~a compound of claim 92~~ {2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine, {2-[(2-aminopropyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine, or 2-([9-(methylethyl)-6-(3-quinolylamino)purin-2-yl]amino)ethan-1-ol.

Claim 110. (Previously presented) The method of claim 109, wherein the inhibition of CDK-2 kinase treats a proliferative disease in which pathogenesis involves abnormal cell proliferation.

Claims 111 -114 are canceled.